Launching in November | New patients: 30% off your first 3 months. Veterans: 30% off for life. |
Launching in November | New patients: 30% off your first 3 months. Veterans: 30% off for life. |
A once-weekly dual-action injection that targets two hormone pathways to support significant, physician-monitored weight loss.
Tirzepatide acts on both GLP-1 and GIP receptors, a dual mechanism that many members find produces stronger appetite suppression and metabolic benefit than single-pathway therapies. Delivered as a once-weekly subcutaneous injection, dosing is gradually titrated upward under provider supervision.
TYPICAL TITRATION RANGE
INJECTION FREQUENCY
BETWEEN DOSE ADJUSTMENTS
Targets two hormone receptors for a stronger satiety effect.
Supports improvements in blood sugar and cardiometabolic health.
Many members see substantial results when paired with lifestyle changes.
Dose increases are paced to your tolerance, not a fixed schedule.
“It’s a shortcut that does all the work for you.”
Tirzepatide reduces appetite, but sustainable results still depend on nutrition and activity habits your provider helps you build.
“Tirzepatide and semaglutide are interchangeable.”
They work through different (though overlapping) mechanisms; your provider helps determine which fits your metabolic profile best.
“You’ll regain everything the moment you stop.”
Your provider builds a maintenance plan, including possible dose tapering, to support keeping weight off long-term.
Bloodwork and a health questionnaire confirm tirzepatide is appropriate and safe for you.
Treatment begins at a low dose to let your body adjust before any increase.
Your provider gradually increases your dose roughly every 4 weeks based on your response and tolerance.
30% OFF FOR LIFE.
to receive ongoing discounts.